Cargando…
The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2 Diabetes Mellitus
Hyperuricemia is a common comorbidity in patients with type 2 diabetes mellitus (T2DM), as insulin resistance (IR) or hyperinsulinemia is associated with higher serum uric acid (SUA) levels due to decreased uric acid (UA) secretion, and SUA vice versa is an important risk factor that promotes the oc...
Autores principales: | Dong, Meiyuan, Chen, Huiling, Wen, Song, Yuan, Yue, Yang, Liling, Xu, Dongxiang, Zhou, Ligang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938669/ https://www.ncbi.nlm.nih.gov/pubmed/36820272 http://dx.doi.org/10.2147/DMSO.S399343 |
Ejemplares similares
-
The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance
por: Dong, Meiyuan, et al.
Publicado: (2023) -
The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors
por: Dong, Meiyuan, et al.
Publicado: (2022) -
Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
por: Kochanowska, Anna, et al.
Publicado: (2023) -
Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients
por: Ohashi, Naro, et al.
Publicado: (2020) -
Factors Influencing Change in Serum Uric Acid After Administration of the Sodium‐Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus
por: Chino, Yukihiro, et al.
Publicado: (2021)